BR0213554A - Timosina para aumento da imunização genética - Google Patents
Timosina para aumento da imunização genéticaInfo
- Publication number
- BR0213554A BR0213554A BR0213554-0A BR0213554A BR0213554A BR 0213554 A BR0213554 A BR 0213554A BR 0213554 A BR0213554 A BR 0213554A BR 0213554 A BR0213554 A BR 0213554A
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- virus
- thymosin
- genetic immunization
- increased genetic
- Prior art date
Links
- 102000007501 Thymosin Human genes 0.000 title abstract 4
- 108010046075 Thymosin Proteins 0.000 title abstract 4
- 230000003053 immunization Effects 0.000 title abstract 4
- 238000002649 immunization Methods 0.000 title abstract 3
- 230000002068 genetic effect Effects 0.000 title abstract 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
"TIMOSINA PARA AUMENTO DA IMUNIZAçãO GENéTICA". A presente invenção descreve o uso de timosina para aumento das respostas imunes celulares ao vírus da hepatite C. Métodos para imunização de um indivíduo suscetível à infecção pelo vírus da hepatite C contra tal infecção compreendendo administração ao indivíduo de um ou mais polinucleotídeos que codificam um ou mais peptídeos do vírus da hepatite C, em combinação com uma ou mais timosinas, são descritos. Composições adequadas para imunização contra o vírus da hepatite C, compreendendo um ou mais polinucleotídeos que codificam um ou mais peptídeos do vírus da hepatite C e uma ou mais timosinas, são também descritas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33063801P | 2001-10-26 | 2001-10-26 | |
PCT/US2002/034535 WO2003035010A2 (en) | 2001-10-26 | 2002-10-28 | Thymosin augmentation of genetic immunization |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0213554A true BR0213554A (pt) | 2004-10-26 |
Family
ID=23290629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0213554-0A BR0213554A (pt) | 2001-10-26 | 2002-10-28 | Timosina para aumento da imunização genética |
Country Status (21)
Country | Link |
---|---|
US (1) | US20050054845A1 (pt) |
EP (1) | EP1448223B1 (pt) |
JP (1) | JP2005506997A (pt) |
KR (1) | KR100902197B1 (pt) |
CN (1) | CN1269524C (pt) |
AT (1) | ATE382365T1 (pt) |
BR (1) | BR0213554A (pt) |
CA (1) | CA2464795A1 (pt) |
CY (1) | CY1107371T1 (pt) |
DE (1) | DE60224435T2 (pt) |
DK (1) | DK1448223T3 (pt) |
EA (1) | EA006743B1 (pt) |
ES (1) | ES2299626T3 (pt) |
IL (1) | IL161603A0 (pt) |
MX (1) | MXPA04003867A (pt) |
NO (1) | NO20042124L (pt) |
NZ (1) | NZ532863A (pt) |
PL (1) | PL370453A1 (pt) |
PT (1) | PT1448223E (pt) |
UA (1) | UA81613C2 (pt) |
WO (1) | WO2003035010A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1835931A4 (en) * | 2004-12-06 | 2008-12-17 | Sciclone Pharmaceuticals Inc | ALPHA THYMOSINE PEPTIDES AS CANCER VACCINE ADJUVANTIES |
US8716012B2 (en) | 2009-05-08 | 2014-05-06 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4079127A (en) * | 1976-10-28 | 1978-03-14 | Board Of Regents Of The University Of Texas | Thymosin alpha 1 |
US4116951A (en) * | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | [Asn2 ]-thymosin α1 and analogs thereof |
US4148788A (en) * | 1978-01-23 | 1979-04-10 | Hoffmann-La Roche Inc. | Synthesis of thymosin α1 |
DE2919592A1 (de) * | 1979-05-15 | 1981-01-15 | Max Planck Gesellschaft | Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon |
TW224053B (pt) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US6288033B1 (en) * | 1998-09-25 | 2001-09-11 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir |
-
2002
- 2002-10-28 PL PL02370453A patent/PL370453A1/xx unknown
- 2002-10-28 DE DE60224435T patent/DE60224435T2/de not_active Expired - Lifetime
- 2002-10-28 PT PT02795564T patent/PT1448223E/pt unknown
- 2002-10-28 DK DK02795564T patent/DK1448223T3/da active
- 2002-10-28 UA UA20040503963A patent/UA81613C2/ru unknown
- 2002-10-28 ES ES02795564T patent/ES2299626T3/es not_active Expired - Lifetime
- 2002-10-28 JP JP2003537579A patent/JP2005506997A/ja active Pending
- 2002-10-28 AT AT02795564T patent/ATE382365T1/de not_active IP Right Cessation
- 2002-10-28 US US10/493,411 patent/US20050054845A1/en not_active Abandoned
- 2002-10-28 CA CA002464795A patent/CA2464795A1/en not_active Abandoned
- 2002-10-28 KR KR1020047006231A patent/KR100902197B1/ko not_active IP Right Cessation
- 2002-10-28 WO PCT/US2002/034535 patent/WO2003035010A2/en active IP Right Grant
- 2002-10-28 NZ NZ532863A patent/NZ532863A/en unknown
- 2002-10-28 IL IL16160302A patent/IL161603A0/xx unknown
- 2002-10-28 EA EA200400534A patent/EA006743B1/ru not_active IP Right Cessation
- 2002-10-28 CN CNB028212770A patent/CN1269524C/zh not_active Expired - Fee Related
- 2002-10-28 EP EP02795564A patent/EP1448223B1/en not_active Expired - Lifetime
- 2002-10-28 MX MXPA04003867A patent/MXPA04003867A/es active IP Right Grant
- 2002-10-28 BR BR0213554-0A patent/BR0213554A/pt not_active IP Right Cessation
-
2004
- 2004-05-24 NO NO20042124A patent/NO20042124L/no not_active Application Discontinuation
-
2008
- 2008-03-28 CY CY20081100354T patent/CY1107371T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20050054845A1 (en) | 2005-03-10 |
JP2005506997A (ja) | 2005-03-10 |
CY1107371T1 (el) | 2012-12-19 |
DK1448223T3 (da) | 2008-02-18 |
CN1269524C (zh) | 2006-08-16 |
WO2003035010A3 (en) | 2003-12-04 |
PT1448223E (pt) | 2008-01-23 |
EA006743B1 (ru) | 2006-04-28 |
IL161603A0 (en) | 2004-09-27 |
CA2464795A1 (en) | 2003-05-01 |
EP1448223A2 (en) | 2004-08-25 |
NO20042124L (no) | 2004-05-24 |
EA200400534A1 (ru) | 2004-12-30 |
ES2299626T3 (es) | 2008-06-01 |
PL370453A1 (en) | 2005-05-30 |
KR20040089075A (ko) | 2004-10-20 |
KR100902197B1 (ko) | 2009-06-11 |
MXPA04003867A (es) | 2005-06-17 |
EP1448223A4 (en) | 2005-11-16 |
WO2003035010A2 (en) | 2003-05-01 |
ATE382365T1 (de) | 2008-01-15 |
DE60224435T2 (de) | 2009-01-02 |
NZ532863A (en) | 2006-07-28 |
DE60224435D1 (de) | 2008-02-14 |
CN1604789A (zh) | 2005-04-06 |
EP1448223B1 (en) | 2008-01-02 |
UA81613C2 (ru) | 2008-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9901186A2 (hu) | Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra | |
DK0587780T3 (da) | Smitstof, som forårsager Mystery Swine Disease, vaccinepræparater og diagnostiske sæt | |
BR9913446A (pt) | Produtos de aglicona e métodos de uso | |
MXPA02011545A (es) | Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela. | |
MXPA06013388A (es) | Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna. | |
ATE103297T1 (de) | Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea. | |
MXPA05005203A (es) | Vacuna contra vhc. | |
DE69432137D1 (de) | Impfstoff gegen Geflügelkokzidose | |
BR0207018A (pt) | Leptina modificada com imunogenicidade reduzida | |
BR0016129A (pt) | Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto | |
DE69635472D1 (de) | Impfstoff gegen Geflügelkokzidose | |
ATE319833T1 (de) | Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus | |
BR0207704A (pt) | Alfa interferon modificado com imunogenicidade reduzida | |
SE9604581D0 (sv) | An agent against cancer and virus infections | |
BR0213554A (pt) | Timosina para aumento da imunização genética | |
DE69521007D1 (de) | Impfstoff gegen Geflügelkokzidose | |
BRPI0410655A (pt) | composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação | |
BR0112486A (pt) | Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv | |
KR960700741A (ko) | 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment) | |
BR0016740A (pt) | Antìgenos de esporozoìto de cryptosporidium | |
BRPI0514274A (pt) | vìrus de varìola aviária recombinante e composição farmacêutica para induzir uma resposta imune celular especìfica contra o vhc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |